Clik here to view.
Three months after delisting, NGM Bio is back with $122M for slimmed-down...
NGM Biopharmaceuticals is pushing ahead with two of its 10 clinical-stage programs after the drug developer was taken off the Nasdaq by one of its original investors, The Column Group, back in April....
View ArticleRoche declares early win for oral GLP-1 drug it bought from Carmot
Roche’s $2.7 billion acquisition of Carmot Therapeutics delivered another success this week. The Swiss pharma said Wednesday morning that its oral GLP-1 receptor agonist produced positive weight loss...
View ArticleAI drug development company gets $80M backing from Pfizer, Nvidia and Thermo...
Pfizer, Nvidia and Thermo Fisher have pitched in to help a machine learning firm amplify its AI approach, which could help biopharma companies better succeed in drug development. CytoReason will use...
View ArticleClik here to view.
Cassava founder and CEO resigns as federal probes progress
Cassava Sciences founder and CEO Remi Barbier is resigning amid two federal probes into the company, which said it’s looking for a new leader. Remi Barbier The news, announced Wednesday, marks the end...
View ArticleHuman challenge trial company hVIVO looks to buy small CROs
LONDON – Viral challenge study service provider hVIVO is in “search mode” to buy small contract research organizations (CROs) to help reach its goal of £100 million ($130 million) in revenue by 2028,...
View ArticleSK to pay up to $571M in new radiopharma deal; Aslan lets go of all employees
Plus, news about Aclaris, OMERS Life Sciences, Draupnir Bio, Pharnext and Actuate: SK Biopharmaceuticals licenses Full-Life’s radiopharma drug: The deal — which is worth $571.5 million in upfront and...
View ArticleBig three PBMs will testify before Congress next week, following FTC report
Pharmacy benefit manager executives from Cigna, CVS Health and UnitedHealth Group are scheduled to testify before Congress on July 23, giving lawmakers a chance to question the companies after a...
View ArticleGilead chief medical officer Merdad Parsey to leave company early next year
Merdad Parsey, Gilead’s chief medical officer, will leave the company at a time when its pipeline has stalled and it’s faced several major stumbles in cancer drug development. He is staying on until...
View ArticleClik here to view.
Thyme Care scores $480M valuation in new funding round
(This story is from our new Health Tech newsletter. If you’d like to sign up, just click here.) Thyme Care’s latest funding round bumped its valuation to $480 million, more than double what it was a...
View ArticleFDA announces rare disease hub in bid to streamline treatment paths
The FDA will launch a rare disease center to unify its policies and find new ways to evaluate drugs that can pose a regulatory dilemma, it announced Wednesday. The new Rare Disease Innovation Hub comes...
View ArticleJ&J has its final offer in hand from the government over IRA pricing
Johnson & Johnson said the final price offers it has received under the IRA won’t affect the long-term sales growth projection it gave last year, making it the latest drugmaker to suggest it can...
View ArticleMerck asks DC federal court for IRA decision 'as soon as practicable'
Merck was the first pharmaceutical company to file suit against the Inflation Reduction Act in June 2023. But more than a year later, it still doesn’t have a decision. On Wednesday, the company asked...
View ArticleClik here to view.
Exclusive: TMRW Life Sciences raises $28M Series D to upgrade storage for egg...
(This story is from our new Health Tech newsletter. If you’d like to sign up, just click here.) TMRW Life Sciences has raised more money for its technology for freezing, tracking and monitoring eggs...
View ArticleClik here to view.
FDA blocks Agenus' accelerated approval plans for CTLA-4/PD-1 combo
Agenus is shelving immediate plans for a confirmatory Phase 3 study for its lead immunotherapy program after the FDA “discouraged” it from filing for accelerated approval and asked for a “definitive...
View ArticleNovartis on 'streamlining' development, MorphoSys drug and radioligand...
More than two years after Novartis first announced a global restructuring that affected 8,000 positions, the pharma giant says its workforce has settled into the simplified structure befitting its...
View ArticleClik here to view.
KRAS cancer drug eased symptoms of rare and serious blood vessel condition in...
The advent of new targeted oncology therapies may benefit more than just cancer patients. Two patients with severe arteriovenous malformations — an ultra-rare condition where a group of blood vessels...
View ArticleClik here to view.
#ASRS24: Roche touts Phase 3 Susvimo data in diabetes-related ophthalmic...
Roche has unveiled new two-year data from late-stage studies of its ocular implant Susvimo in patients with diabetic eye conditions, as the Swiss pharma works to relaunch the product in a separate...
View ArticleClik here to view.
GoodRx launches discount for Boehringer Ingelheim's Humira biosimilar
Boehringer Ingelheim has partnered with GoodRx to offer the drugmaker’s Humira biosimilar, adalimumab-adbm, in another move by manufacturers to try and wedge themselves into a market still dominated by...
View ArticleClik here to view.
Phathom wins label expansion on heartburn drug to include non-erosive patients
Phathom Pharmaceuticals is digesting news of an expanded label for its heartburn drug Voquezna. The FDA on Wednesday afternoon approved the drug for the relief of heartburn associated with non-erosive...
View ArticleSanofi seeks deeper roots in India with €400M hub expansion
India is soon to become host to Sanofi’s largest global capacity center as the French pharma plans to spend €400 million ($437 million) and more than double its workforce in Hyderabad. The company is...
View Article